secwatch.observer — SEC 8-K summary
======================================

Issuer:     AERIE PHARMACEUTICALS INC (—)
CIK:        0001337553
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001140361-22-042430
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerie Pharmaceuticals completes acquisition by Alcon for $15.25/share; stock to be delisted
--------------------------------------------------------------------------------

- Merger closed Nov 21, 2022; Aerie shareholders receive $15.25 per share in cash.
- Company to delist from Nasdaq and deregister securities under Exchange Act.
- Board and management replaced; David Endicott named CEO, Timothy Stonesifer CFO.
- Convertible notes amended; conversion consideration set at $15.25 cash per $1,000 principal.
- Stockholders approved merger at special meeting on Nov 17, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337553/000114036122042430/0001140361-22-042430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337553/000114036122042430/brhc10044372_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-042430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer